Compare WVE & GEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WVE | GEL |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil Refining/Marketing |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2015 | 1996 |
| Metric | WVE | GEL |
|---|---|---|
| Price | $7.07 | $15.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 2 |
| Target Price | ★ $29.81 | $19.50 |
| AVG Volume (30 Days) | ★ 3.9M | 255.2K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 4.19% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,704,000.00 | ★ $2,912,770,000.00 |
| Revenue This Year | N/A | $12.12 |
| Revenue Next Year | $85.67 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 149.43 | 43.60 |
| 52 Week Low | $5.02 | $14.55 |
| 52 Week High | $21.73 | $18.64 |
| Indicator | WVE | GEL |
|---|---|---|
| Relative Strength Index (RSI) | 39.03 | 29.54 |
| Support Level | $6.81 | $14.93 |
| Resistance Level | $7.67 | $16.42 |
| Average True Range (ATR) | 0.36 | 0.48 |
| MACD | 0.15 | -0.10 |
| Stochastic Oscillator | 28.00 | 9.88 |
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Genesis Energy LP focuses on the midstream segment of the crude oil and natural gas industry. It offers various services to crude oil and natural gas producers, and industrial and commercial enterprises. The company's reportable segments are: Offshore pipeline transportation, Marine transportation, and Onshore transportation and services. Maximum revenue is generated from the Offshore pipeline transportation segment, which includes the transportation and processing of crude oil and natural gas in the Gulf of America. The Marine transportation segment provides waterborne transportation of petroleum products and crude oil throughout North America; and the Onshore transportation and services segment deals with crude oil logistics, sour gas processing, and sells sulfur byproducts.